Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.

Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.

J Headache Pain. 2018 Feb 5;19(1):13. doi: 10.1186/s10194-018-0840-8.

2.

Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry.

Barloese M, Petersen A, Stude P, Jürgens T, Jensen RH, May A.

J Headache Pain. 2018 Jan 18;19(1):6. doi: 10.1186/s10194-017-0828-9.

3.

Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID).

Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC, Desai PR, Ortmeier BG, Sapra S.

Health Qual Life Outcomes. 2017 Nov 17;15(1):224. doi: 10.1186/s12955-017-0799-1.

4.

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design.

Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC.

J Headache Pain. 2017 Oct 4;18(1):101. doi: 10.1186/s10194-017-0787-1.

5.

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.

Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.

J Headache Pain. 2017 Dec;18(1):78. doi: 10.1186/s10194-017-0784-4. Epub 2017 Aug 1.

6.

Chiropractic spinal manipulative therapy for cervicogenic headache: a single-blinded, placebo, randomized controlled trial.

Chaibi A, Knackstedt H, Tuchin PJ, Russell MB.

BMC Res Notes. 2017 Jul 24;10(1):310. doi: 10.1186/s13104-017-2651-4.

7.

OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.

Ranoux D, Martiné G, Espagne-Dubreuilh G, Amilhaud-Bordier M, Caire F, Magy L.

J Headache Pain. 2017 Dec;18(1):75. doi: 10.1186/s10194-017-0781-7. Epub 2017 Jul 21.

8.

Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.

Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, Sarchielli P, Tedeschi G, Martelletti P, Cortelli P.

J Headache Pain. 2017 Dec;18(1):66. doi: 10.1186/s10194-017-0773-7. Epub 2017 Jun 30.

9.

Tricyclic antidepressants for preventing migraine in adults.

Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD.

Medicine (Baltimore). 2017 Jun;96(22):e6989. doi: 10.1097/MD.0000000000006989. Review.

10.
11.

Chiropractic spinal manipulative therapy for migraine: a three-armed, single-blinded, placebo, randomized controlled trial.

Chaibi A, Benth JŠ, Tuchin PJ, Russell MB.

Eur J Neurol. 2017 Jan;24(1):143-153. doi: 10.1111/ene.13166. Epub 2016 Oct 2.

12.

Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients.

Miller S, Watkins L, Matharu M.

J Headache Pain. 2016 Dec;17(1):68. doi: 10.1186/s10194-016-0659-0. Epub 2016 Jul 30.

13.

Safety and efficacy of cervical 10 kHz spinal cord stimulation in chronic refractory primary headaches: a retrospective case series.

Lambru G, Trimboli M, Palmisani S, Smith T, Al-Kaisy A.

J Headache Pain. 2016 Dec;17(1):66. doi: 10.1186/s10194-016-0657-2. Epub 2016 Jul 8.

14.

Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache.

Jürgens TP, Barloese M, May A, Láinez JM, Schoenen J, Gaul C, Goodman AM, Caparso A, Jensen RH.

Cephalalgia. 2017 Apr;37(5):423-434. doi: 10.1177/0333102416649092. Epub 2016 May 9. Erratum in: Cephalalgia. 2016 Sep 1;:.

15.

Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.

Bratbak DF, Nordgård S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, Folvik M, Tronvik E.

Cephalalgia. 2017 Apr;37(4):356-364. doi: 10.1177/0333102416648328. Epub 2016 May 6.

16.

A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.

Negro A, Curto M, Lionetto L, Martelletti P.

J Headache Pain. 2015;17:1. doi: 10.1186/s10194-016-0591-3. Epub 2016 Jan 21.

17.

OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.

Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P.

Springerplus. 2015 Dec 30;4:826. doi: 10.1186/s40064-015-1636-9. eCollection 2015.

18.

Chiropractic spinal manipulative therapy for cervicogenic headache: a study protocol of a single-blinded placebo-controlled randomized clinical trial.

Chaibi A, Benth JŠ, Tuchin PJ, Russell MB.

Springerplus. 2015 Dec 16;4:779. doi: 10.1186/s40064-015-1567-5. eCollection 2015.

19.

Chiropractic spinal manipulative therapy for migraine: a study protocol of a single-blinded placebo-controlled randomised clinical trial.

Chaibi A, Šaltytė Benth J, Tuchin PJ, Russell MB.

BMJ Open. 2015 Nov 19;5(11):e008095. doi: 10.1136/bmjopen-2015-008095.

20.

Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse.

Ahmed F, Zafar HW, Buture A, Khalil M.

Springerplus. 2015 Oct 9;4:589. doi: 10.1186/s40064-015-1386-8. eCollection 2015.

Supplemental Content

Support Center